253 related articles for article (PubMed ID: 33902700)
1. A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer.
Ruan W; Chen X; Huang M; Wang H; Chen J; Liang Z; Zhang J; Yu Y; Chen S; Xu S; Hu T; Li X; Guo Y; Jiang Z; Chen Z; Huang J; Lin T; Fan JB
Clin Epigenetics; 2021 Apr; 13(1):91. PubMed ID: 33902700
[TBL] [Abstract][Full Text] [Related]
2. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer.
Chen X; Zhang J; Ruan W; Huang M; Wang C; Wang H; Jiang Z; Wang S; Liu Z; Liu C; Tan W; Yang J; Chen J; Chen Z; Li X; Zhang X; Xu P; Chen L; Xie R; Zhou Q; Xu S; Irwin DL; Fan JB; Huang J; Lin T
J Clin Invest; 2020 Dec; 130(12):6278-6289. PubMed ID: 32817589
[TBL] [Abstract][Full Text] [Related]
3. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
[TBL] [Abstract][Full Text] [Related]
4. UroMark-a urinary biomarker assay for the detection of bladder cancer.
Feber A; Dhami P; Dong L; de Winter P; Tan WS; Martínez-Fernández M; Paul DS; Hynes-Allen A; Rezaee S; Gurung P; Rodney S; Mehmood A; Villacampa F; de la Rosa F; Jameson C; Cheng KK; Zeegers MP; Bryan RT; James ND; Paramio JM; Freeman A; Beck S; Kelly JD
Clin Epigenetics; 2017; 9():8. PubMed ID: 28163793
[TBL] [Abstract][Full Text] [Related]
5. A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.
Hermanns T; Savio AJ; Olkhov-Mitsel E; Mari A; Wettstein MS; Saba K; Bhindi B; Kuk C; Poyet C; Wild PJ; Noon A; Bashir S; Juvet T; Rendon RA; Waltregny D; van der Kwast T; Finelli A; Kulkarni GS; Fleshner NE; Lo K; Bapat B; Zlotta AR
Urol Oncol; 2020 Jun; 38(6):603.e1-603.e7. PubMed ID: 32081560
[TBL] [Abstract][Full Text] [Related]
6. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples.
Piatti P; Chew YC; Suwoto M; Yamada T; Jara B; Jia XY; Guo W; Ghodoussipour S; Daneshmand S; Ahmadi H; Rice J; Bhasin J; Holloway F; Tsai Y; Chihara Y; Liang G
Clin Epigenetics; 2021 Apr; 13(1):84. PubMed ID: 33882992
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study.
Xiao Y; Ju L; Qian K; Jin W; Wang G; Zhao Y; Jiang W; Liu N; Wu K; Peng M; Cao R; Li S; Shi H; Gong Y; Zheng H; Liu T; Luo Y; Ma H; Chang L; Li G; Cao X; Tian Y; Xu Z; Yang Z; Shan L; Guo Z; Yao D; Zhou X; Chen X; Guo Z; Liu D; Xu S; Ji C; Yu F; Hong X; Luo J; Cao H; Zhang Y; Wang X
Clin Transl Med; 2022 Aug; 12(8):e1008. PubMed ID: 35968916
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Sensitive Urine DNA-Based PENK Methylation Test for Detecting Bladder Cancer in Patients with Hematuria.
Oh TJ; Lee JY; Seo Y; Woo MA; Lim JS; Na YG; Song KH; Bang BR; Lee JJ; Shin JH; An S
J Mol Diagn; 2023 Sep; 25(9):646-654. PubMed ID: 37330048
[TBL] [Abstract][Full Text] [Related]
11. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine.
Zuiverloon TC; Beukers W; van der Keur KA; Munoz JR; Bangma CH; Lingsma HF; Eijkemans MJ; Schouten JP; Zwarthoff EC
BJU Int; 2012 Mar; 109(6):941-8. PubMed ID: 21756281
[TBL] [Abstract][Full Text] [Related]
12. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.
van Kessel KE; Beukers W; Lurkin I; Ziel-van der Made A; van der Keur KA; Boormans JL; Dyrskjøt L; Márquez M; Ørntoft TF; Real FX; Segersten U; Malats N; Malmström PU; Van Criekinge W; Zwarthoff EC
J Urol; 2017 Mar; 197(3 Pt 1):590-595. PubMed ID: 27746284
[TBL] [Abstract][Full Text] [Related]
13. Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA.
Ward DG; Baxter L; Ott S; Gordon NS; Wang J; Patel P; Piechocki K; Silcock L; Sale C; Zeegers MP; Cheng KK; James ND; Bryan RT;
Eur Urol Oncol; 2023 Feb; 6(1):67-75. PubMed ID: 35410825
[TBL] [Abstract][Full Text] [Related]
14. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.
Kim YH; Yan C; Lee IS; Piao XM; Byun YJ; Jeong P; Kim WT; Yun SJ; Kim WJ
Investig Clin Urol; 2016 Mar; 57(2):106-12. PubMed ID: 26981592
[TBL] [Abstract][Full Text] [Related]
15. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
16. Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.
Fantony JJ; Longo TA; Gopalakrishna A; Owusu R; Lance RS; Foo WC; Inman BA; Abern MR
Cancer Biomark; 2017; 18(4):381-387. PubMed ID: 28106542
[TBL] [Abstract][Full Text] [Related]
17. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
18. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments.
Chung W; Bondaruk J; Jelinek J; Lotan Y; Liang S; Czerniak B; Issa JP
Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1483-91. PubMed ID: 21586619
[TBL] [Abstract][Full Text] [Related]
19. Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation.
Hentschel AE; Beijert IJ; Bosschieter J; Kauer PC; Vis AN; Lissenberg-Witte BI; van Moorselaar RJA; Steenbergen RDM; Nieuwenhuijzen JA
Clin Epigenetics; 2022 Feb; 14(1):19. PubMed ID: 35123558
[TBL] [Abstract][Full Text] [Related]
20. A urinary microRNA (miR) signature for diagnosis of bladder cancer.
Hofbauer SL; de Martino M; Lucca I; Haitel A; Susani M; Shariat SF; Klatte T
Urol Oncol; 2018 Dec; 36(12):531.e1-531.e8. PubMed ID: 30322728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
